EXTRANCHECK: PRE-LICENSE CHECK: NEW A-IKOR LIMITED

UNCLAS HONG KONG 002680 SIPDIS USDOC FOR 532/OEA/LHINES/DFARROW USDOC FOR 3132 FOR FCS/OIO REGIONAL DIRECTOR WILLIAM ZARIT BICE FOR OFFICE OF STRATEGIC INVESTIGATIONS SIPDIS E.O. 12958: N/A TAGS: BMGT BEXP HK ETRD ETTC SUBJECT: EXTRANCHECK: PRE-LICENSE CHECK: NEW A-IKOR LIMITED REF: A) USDOC 09155 B) D384167 ¶1. Unauthorized disclosure of the information provided below is prohibited by Section 12C of the Export Administration Act. ¶2. As per reftel A request and at the direction of the Office of Enforcement Analysis (OEA) of the USDOC Bureau of Industry and Security (BIS),Export Control Officer Philip Ankel (ECO),conducted a pre-license check at New A-Ikor Limited, 3/F, HKIB, 2 Biotechnology Avenue, Tai Po Raod, Shatin, Hong Kong (A-Ikor). The purpose of the visit was to determine the suitability of A-Ikor to be a recipient of membrane filtration cassettes that are the subject of export license application D384167. The items (ECCN 2B352) are valued at USD $11,000 and are controlled for chemical and biological weapons reasons (CB). The license applicant is Pall Corporation of East Hills, New York. ¶3. On October 17, 2007, ECO visited New A-Ikor at the address listed above and met with Mr. Bing Lou Wong, Chief Technical Officer. According to Mr. Wong, the company was established in 2007 and is involved in the bio-pharmaceutical industry with a focus on oxygen therapeutic products. It has gained exclusive worldwide manufacturing rights to U.S. company Ikor Inc.'s oxygen therapeutics (more information on the U.S. entity is available at www.ikorlife.com). New A-Ikor owns a biologics manufacturing plant in Hong Kong (that it recently acquired from Advantek Biologics (HK) Limited). More information concerning A-Ikor is available at www.aikor.com. ¶4. Mr. Wong stated that the membrane filtration cassettes would be used in the production of hemoglobin replacement therapies (essentially, a replacement hemoglobin delivery mechanism manufactured with bovine cells). The primary initial market is for animal use in Europe to treat, for example, dogs that have ingested rat poison. Mr. Wong provided ECO with a tour of the production facility, which is located at the address referenced above. ¶5. At the tie visited, A-Ikor appeared to be a suitable recipient of the subject controlled items since it cooperated fully with the PLC and provided substantial information on A-Ikor's proposed use of the items in Hong Kong. In addition, A-Ikor operates a line a business that appears consistent with the potential use of the ordered items. The ECO recommends that this PLC be classified as Favorable. Cunningham